Abstract： Objective： To observe the clinical effect of Wuling Capsules combined with Tenofovir for chronic hepatitis B with liver depression and spleen deficiency syndrome and its effect on liver fibrosis. Methods： A total of 78 cases of patients with chronic hepatitis B complicated with liver fibrosis were randomly divided into the treatment group and the control group，with 39 cases in each group. The control group was treated with tenofovir，and the treatment group was additionally treated with Wuling Capsules based on the treatment of the control group. Both groups were treated for 6 months. The clinical effects， the indexes of liver fibrosis including hyaluronic acid (HA)，typeⅢprocollagen (PCⅢ)，typeⅣ collagen (Ⅳ-C) and laminin (LN)，the negative conversion rate of hepatitis B e antigen (HBeAg) and the negative conversion rate of hepatitis B virus (HBV)- DNA load were compared between the two groups. Results： The total clinical effective rate was 92.31% in the treatment group， significantly higher than that of 71.79% in the control group， the difference being significant (P＜0.05). Before treatment， there was no significant difference being found in the comparison of the levels of HA，PCⅢ，Ⅳ-C and LN in serum between the two groups (P＞0.05). After treatment， the levels of HA， PC Ⅲ， Ⅳ- C and LN in the two groups were significantly decreased when compared with those before treatment (P＜0.05)， and the 4 indexes in the treatment group were lower than those in the control group (P＜0.05). The negative conversion rates of HBeAg and HBV- DNA were 53.85% and 76.92% respectively in the treatment group，and were 28.21% and 51.28% respectively in the control group，differences being significant (P＜0.05). Conclusion：Wuling Capsules combined with Tenofovir for chronic hepatitis B with liver depression and spleen deficiency syndrome has a significant curative effect，and can increase the negative conversion rate of HBeAg，inhibit the replication of HBV-DNA，and improve liver fibrosis in patients.